Association of Circulating Cell-Free Mitochondrial DNA With Sudden Sensorineural Hearing Loss.

IF 2.6 3区医学 Q1 OTORHINOLARYNGOLOGY

Otolaryngology- Head and Neck Surgery Pub Date : 2025-07-01 Epub Date: 2025-03-24 DOI:10.1002/ohn.1238

Chao-Hui Yang, Ming-Yu Yang, Wei-Che Lin, Chung-Feng Hwang, Yu-Tsai Lin, Ching-Nung Wu, I-Ya Chen, Ming-Hsien Tsai

{"title":"Association of Circulating Cell-Free Mitochondrial DNA With Sudden Sensorineural Hearing Loss.","authors":"Chao-Hui Yang, Ming-Yu Yang, Wei-Che Lin, Chung-Feng Hwang, Yu-Tsai Lin, Ching-Nung Wu, I-Ya Chen, Ming-Hsien Tsai","doi":"10.1002/ohn.1238","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the association of circulating cell-free mitochondrial DNA (ccf-mtDNA) levels with the severity and treatment outcomes of sudden sensorineural hearing loss (SSNHL).Study design: Observational prospective study.Setting: Tertiary academic medical center.Methods: Plasma samples were collected from patients diagnosed with SSNHL in the morning before steroid treatment, as well as from healthy controls. A quantitative polymerase chain reaction was used to measure ccf-mtDNA levels, expressed as log copy numbers per milliliter. Treatment outcomes were evaluated using hearing gain, percentage of recovery, and Siegel's criteria.Results: The study included 80 subjects, including 50 patients and 30 healthy controls. The mean (SD) plasma ccf-mtDNA level was 8.1 (0.35), which was significantly higher than 7.78 (0.65) controls (95% CI: 0.097-0.542). Patients with good recovery exhibited significantly higher pretreatment ccf-mtDNA levels compared to those with poor recovery (mean [SD] score: 8.29 [0.34] vs 8.02 [0.33]; 95% CI: 0.04-0.48). Ccf-mtDNA levels were positively associated with hearing gain (r = 0.486, 95% CI: 0.227-0.663) and percentage of recovery (r = 0.361, 95% CI: 0.103-0.574). Multivariate analyses revealed that less than 7 days from onset of hearing loss to treatment (odds ratio [OR]: 7.389, 95% CI: 1.324-41.239) and higher ccf-mtDNA levels (OR: 24.634, 95% CI: 1.878-323.163) were independent predictors for good recovery.Conclusion: Plasma ccf-mtDNA levels were elevated in patients with SSNHL and were significantly associated with better treatment outcomes following steroid therapy. These findings suggest that ccf-mtDNA levels may serve as a predictive biomarker for SSNHL treatment outcomes, paving the way for personalized therapeutic strategies.","PeriodicalId":19707,"journal":{"name":"Otolaryngology- Head and Neck Surgery","volume":" ","pages":"193-200"},"PeriodicalIF":2.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Otolaryngology- Head and Neck Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ohn.1238","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the association of circulating cell-free mitochondrial DNA (ccf-mtDNA) levels with the severity and treatment outcomes of sudden sensorineural hearing loss (SSNHL).

Study design: Observational prospective study.

Setting: Tertiary academic medical center.

Methods: Plasma samples were collected from patients diagnosed with SSNHL in the morning before steroid treatment, as well as from healthy controls. A quantitative polymerase chain reaction was used to measure ccf-mtDNA levels, expressed as log copy numbers per milliliter. Treatment outcomes were evaluated using hearing gain, percentage of recovery, and Siegel's criteria.

Results: The study included 80 subjects, including 50 patients and 30 healthy controls. The mean (SD) plasma ccf-mtDNA level was 8.1 (0.35), which was significantly higher than 7.78 (0.65) controls (95% CI: 0.097-0.542). Patients with good recovery exhibited significantly higher pretreatment ccf-mtDNA levels compared to those with poor recovery (mean [SD] score: 8.29 [0.34] vs 8.02 [0.33]; 95% CI: 0.04-0.48). Ccf-mtDNA levels were positively associated with hearing gain (r = 0.486, 95% CI: 0.227-0.663) and percentage of recovery (r = 0.361, 95% CI: 0.103-0.574). Multivariate analyses revealed that less than 7 days from onset of hearing loss to treatment (odds ratio [OR]: 7.389, 95% CI: 1.324-41.239) and higher ccf-mtDNA levels (OR: 24.634, 95% CI: 1.878-323.163) were independent predictors for good recovery.

Conclusion: Plasma ccf-mtDNA levels were elevated in patients with SSNHL and were significantly associated with better treatment outcomes following steroid therapy. These findings suggest that ccf-mtDNA levels may serve as a predictive biomarker for SSNHL treatment outcomes, paving the way for personalized therapeutic strategies.

查看原文本刊更多论文

循环无细胞线粒体DNA与突发性感音神经性听力损失的关系。

目的：探讨循环无细胞线粒体DNA （ccf-mtDNA）水平与突发性感音神经性听力损失（SSNHL）严重程度及治疗效果的关系。研究设计：观察性前瞻性研究。环境：三级学术医疗中心。方法：收集SSNHL患者在类固醇治疗前早晨的血浆样本，以及健康对照。定量聚合酶链反应用于测量ccf-mtDNA水平，以每毫升对数拷贝数表示。使用听力增益、恢复百分比和西格尔标准评估治疗结果。结果：本研究纳入80名受试者，其中50名患者和30名健康对照。血浆ccf-mtDNA水平均值（SD）为8.1(0.35)，显著高于对照组的7.78 (0.65)（95% CI: 0.097 ~ 0.542）。恢复良好的患者的预处理ccf-mtDNA水平明显高于恢复较差的患者(平均[SD]评分：8.29[0.34]比8.02 [0.33]；95% ci: 0.04-0.48)。Ccf-mtDNA水平与听力增加（r = 0.486, 95% CI: 0.227-0.663）和恢复百分比（r = 0.361, 95% CI: 0.103-0.574）呈正相关。多因素分析显示，从听力损失发病到治疗不到7天（优势比[OR]: 7.389, 95% CI: 1.324-41.239）和较高的ccf-mtDNA水平（OR: 24.634, 95% CI: 1.878-323.163）是良好恢复的独立预测因素。结论：SSNHL患者血浆ccf-mtDNA水平升高，与类固醇治疗后更好的治疗结果显著相关。这些发现表明ccf-mtDNA水平可以作为SSNHL治疗结果的预测性生物标志物，为个性化治疗策略铺平道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Otolaryngology- Head and Neck Surgery 医学-耳鼻喉科学

CiteScore

6.70

自引率

2.90%

发文量

250

审稿时长

2-4 weeks

期刊介绍： Otolaryngology–Head and Neck Surgery (OTO-HNS) is the official peer-reviewed publication of the American Academy of Otolaryngology–Head and Neck Surgery Foundation. The mission of Otolaryngology–Head and Neck Surgery is to publish contemporary, ethical, clinically relevant information in otolaryngology, head and neck surgery (ear, nose, throat, head, and neck disorders) that can be used by otolaryngologists, clinicians, scientists, and specialists to improve patient care and public health.